

# Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H95FE65A86B3EN.html>

Date: March 2022

Pages: 189

Price: US\$ 2,000.00 (Single User License)

ID: H95FE65A86B3EN

## Abstracts

Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 4, 11, 15, 12 and 2 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Hospital Acquired Pneumonia (HAP) - Overview

Hospital Acquired Pneumonia (HAP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics

Development

AiCuris AG

Allegra Therapeutics GmbH

Antabio SAS

Aridis Pharmaceuticals Inc

Biolytx Pharmaceuticals Corp

Bioversys AG

Cellular Biomedicine Group Inc

Centauri Therapeutics Ltd

Clarametyx Biosciences Inc

ContraFect Corp

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Eldec Pharmaceuticals Inc

Entasis Therapeutics Holdings Inc

Evotec SE

GangaGen Biotechnologies Pvt Ltd

Helperby Therapeutics Group Ltd

Hoth Therapeutics Inc

Hypo-Stream Ltd

La Jolla Pharmaceutical Company

Meiji Seika Pharma Co Ltd

Merck & Co Inc  
Nabriva Therapeutics Plc  
Nosopharm SAS  
Omnix Medical Ltd  
Peptineo  
Pfizer Inc  
Pherecydes Pharma SA  
Phico Therapeutics Ltd  
Pulmobiotics SL  
Qilu Pharmaceutical Co Ltd  
Revagenix Inc  
Shionogi & Co Ltd  
Spero Therapeutics Inc  
Spexis AG  
TGV-Inhalonix Inc  
Therapeutic Systems Research Laboratories Inc  
VenatoRx Pharmaceuticals Inc  
Wockhardt Ltd  
Hospital Acquired Pneumonia (HAP) - Drug Profiles  
(AAI-101 + cefepime) - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
(avibactam + aztreonam) - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
(avibactam sodium + ceftazidime) - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
(cefepime + taniborbactam hydrochloride) - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
(cefepime + zidebactam) - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events

(cilastatin sodium + imipenem + relebactam) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(durlobactam sodium + sulbactam) - Drug Profile

Product Description

Mechanism Of Action

History of Events

ABX-01 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AlloJoin - Drug Profile

Product Description

Mechanism Of Action

History of Events

arbakacin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic for Ventilator Associated Pneumonia - Drug Profile

Product Description

Mechanism Of Action

BP-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

cefiderocol sulfate tosylate - Drug Profile

Product Description

Mechanism Of Action

History of Events

CF-370 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CMTX-101 - Drug Profile

Product Description

Mechanism Of Action

EBX-004 - Drug Profile

Product Description  
Mechanism Of Action  
History of Events  
ELD-607 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
eravacycline dihydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
exeporfinium chloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
FL-058 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
fosfomicin disodium - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
HT-006 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
HY-010B3 - Drug Profile  
Product Description  
Mechanism Of Action  
HY-011B4 - Drug Profile  
Product Description  
Mechanism Of Action  
HY-012B5 - Drug Profile  
Product Description  
Mechanism Of Action  
HY-015B12 - Drug Profile  
Product Description  
Mechanism Of Action



lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

History of Events

levonadifloxacin - Drug Profile

Product Description

Mechanism Of Action

MEMANT-3310 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

History of Events

murepavadin - Drug Profile

Product Description

Mechanism Of Action

History of Events

nacubactam - Drug Profile

Product Description

Mechanism Of Action

History of Events

NOSO-2G - Drug Profile

Product Description

Mechanism Of Action

History of Events

OMN-6 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Panaecin - Drug Profile

Product Description

Mechanism Of Action

History of Events

panobacumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Peptides for Complicated Skin and Skin Structure Infections and Hospital Acquired  
Pneumonia (HAP) - Drug Profile

Product Description

Mechanism Of Action

History of Events

PP-1231 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis,  
Hospital Acquired Pneumonia and Diabetic Foot Infection - Drug Profile

Product Description

Mechanism Of Action

History of Events

Qn-2251 - Drug Profile

Product Description

Mechanism Of Action

rifabutin - Drug Profile

Product Description

Mechanism Of Action

History of Events

SASPjectPT-3.9 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Hospital Acquired Pneumonia (HAP) and Ventilator Associated  
Pneumonia (VAP) - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Hospital-Acquired Pneumonia, Intra-Abdominal and Urinary Tract  
Infections - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

SPR-206 - Drug Profile

Product Description

Mechanism Of Action

History of Events

suvratoxumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

tedizolid phosphate - Drug Profile

Product Description

Mechanism Of Action

History of Events

telavancin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

tosatoxumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

XF-70 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Hospital Acquired Pneumonia (HAP) - Dormant Projects

Hospital Acquired Pneumonia (HAP) - Discontinued Products

Hospital Acquired Pneumonia (HAP) - Product Development Milestones

Featured News & Press Releases

Aug 17, 2021: Venatorx Pharmaceuticals provides update on Cefepime-Taniborbactam

Jun 07, 2021: The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Journal of Pharmacology

Apr 19, 2021: Phico Therapeutics awarded up to \$18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials

Apr 19, 2021: Phico Therapeutics awarded up to \$18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials

Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Recarbrio

Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Recarbrio

Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta

Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta

Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta

Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta

Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jun 01, 2020: FDA accepts Shionogi's Supplemental New Drug Application with Priority Review for FETROJA (cefiderocol) for the Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO's priority pathogens

May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO's priority pathogens

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Companies, 2022 (Contd..3)  
Products under Development by Companies, 2022 (Contd..4)  
Products under Development by Companies, 2022 (Contd..5)  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by AiCuris AG, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Allecra Therapeutics GmbH, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Antabio SAS, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Biolytx Pharmaceuticals Corp, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Bioversys AG, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Cellular Biomedicine Group Inc, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Clarametyx Biosciences Inc, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by ContraFect Corp, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Eldec Pharmaceuticals Inc, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Entasis Therapeutics Holdings Inc, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Evotec SE, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2022  
Hospital Acquired Pneumonia (HAP) - Pipeline by Helperby Therapeutics Group Ltd,

2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Hoth Therapeutics Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Hypo-Stream Ltd, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by La Jolla Pharmaceutical Company,  
2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Merck &amp; Co Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Nosopharm SAS, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Omnix Medical Ltd, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Peptineo, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Pfizer Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Pherecydes Pharma SA, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Phico Therapeutics Ltd, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Pulmobiotics SL, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Revagenix Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi &amp; Co Ltd, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Spexis AG, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Therapeutic Systems Research  
Laboratories Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by VenatoRx Pharmaceuticals Inc, 2022

Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, 2022

Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022

Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022 (Contd..1)

Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022 (Contd..2)

Hospital Acquired Pneumonia (HAP) - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H95FE65A86B3EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H95FE65A86B3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



